|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Collaborator: |
Glaxo Wellcome |
| Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000816 |
Purpose
To determine whether gradual initiation of sulfamethoxazole/trimethoprim (SMX/TMP) reduces the incidence of treatment-limiting adverse reactions compared to the routine initiation of the drugs for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected patients.
Although a number of clinical trials have demonstrated the superiority of SMX/TMP for PCP prophylaxis, the incidence of adverse reactions to this medication is high. In a pilot study in which patients were initiated with SMX/TMP prophylaxis by gradually increasing the dose over 2 weeks, no significant adverse reactions have occurred.
| Condition | Intervention | Phase |
|---|---|---|
|
Pneumonia, Pneumocystis Carinii HIV Infections |
Drug: Sulfamethoxazole-Trimethoprim |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis |
| Estimated Enrollment: | 370 |
Although a number of clinical trials have demonstrated the superiority of SMX/TMP for PCP prophylaxis, the incidence of adverse reactions to this medication is high. In a pilot study in which patients were initiated with SMX/TMP prophylaxis by gradually increasing the dose over 2 weeks, no significant adverse reactions have occurred.
Patients are randomized to receive either gradually increasing doses of SMX/TMP suspension or routine daily initiation of SMX/TMP double strength (DS) tablets for 2 weeks. All patients will then be switched over to receive open-label SMX/TMP DS tablets daily for 10 weeks.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed if clinically indicated:
Allowed for symptomatic treatment of mild study drug toxicity:
Patients must have:
NOTE:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Prior Medication:
Excluded at any time:
Excluded within 4 weeks prior to study entry:
Excluded within 2 weeks prior to study entry:
Contacts and Locations
Show 64 Study Locations| Study Chair: | Para MF | |
| Study Chair: | Dohn MN | |
| Study Chair: | Frame P |
More Information
| Study ID Numbers: | ACTG 268 |
| Study First Received: | November 2, 1999 |
| Last Updated: | January 25, 2006 |
| ClinicalTrials.gov Identifier: | NCT00000816 History of Changes |
| Health Authority: | United States: Federal Government |
|
Trimethoprim-Sulfamethoxazole Combination Pneumonia, Pneumocystis carinii Acquired Immunodeficiency Syndrome AIDS-Related Complex Sulfamethoxazole-Trimethoprim |
|
Anti-Infective Agents Antiprotozoal Agents Sexually Transmitted Diseases, Viral Trimethoprim Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Trimethoprim-Sulfamethoxazole Combination Renal Agents Infection Antimalarials Pneumonia, Pneumocystis Mycoses Antiparasitic Agents Respiratory Tract Diseases Respiratory Tract Infections |
Therapeutic Uses Retroviridae Infections Lung Diseases, Fungal RNA Virus Infections Immune System Diseases Sulfamethoxazole Acquired Immunodeficiency Syndrome Enzyme Inhibitors Anti-Infective Agents, Urinary Folic Acid Antagonists Pharmacologic Actions Immunologic Deficiency Syndromes Virus Diseases Pneumocystis Infections HIV Infections |